Bone quality: A perspective from the food and drug administration
Author:
- 1 June 2006
- journal article
- review article
- Published by Springer Nature in Current Osteoporosis Reports
- Vol. 4 (2) , 76-79
Abstract
Osteoporosis, a disease of compromised bone strength, is a leading cause of fracture, morbidity, and mortality. The past 10 years have resulted in the development of new pharmacologic therapies for the treatment of this disease. Most of these agents have been approved for the treatment of osteoporosis based on placebo-controlled fracture trials. However, recent ethical concerns regarding placebo-controlled trials threaten to derail the development of new, possibly better, treatment options. Novel noninvasive imaging technologies may offer greater insight into the pathophysiology and biomechanics of osteoporosis and fracture. Because of these advances, many hope to find a new biomarker that will predict fracture risk better than the current bone density measurements and that ultimately will replace fracture as the primary endpoint for osteoporosis drug registration trials. This paper discusses the perspective of a Food and Drug Administration reviewer regarding the role of surrogate markers as they relate to the quest for new, safe and efficacious treatments for osteoporosis.Keywords
This publication has 7 references indexed in Scilit:
- Osteoporosis Panel SummaryJournal of Bone and Mineral Research, 2003
- The Food and Drug Administration's Osteoporosis Guidance Document: Past, Present, and FutureJournal of Bone and Mineral Research, 2003
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001
- World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.2000
- World Medical Association Declaration of HelsinkiJAMA, 2000
- Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapyThe American Journal of Medicine, 1993
- Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 1990